Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI.

Frontiers in digital health·2026
Same author

Perspectives from healthcare providers and decision-makers on strategies toward a future hospital: qualitative insights from a group modelling process.

BMC health services research·2026
Same author

Propensity score matched comparison of pancreatoduodenectomy with pancreatogastrostomy versus pancreatojejunostomy: A single institution experience shifting from pancreatogastrostomy to pancreatojejunostomy.

Annals of hepato-biliary-pancreatic surgery·2026
Same author

The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1.

Oncogenesis·2026
Same author

The functional imperative in high-grade glioma.

Experimental & molecular medicine·2026
Same author

Artificial intelligence for breast cancer management.

Communications medicine·2026

Related Experiment Video

Updated: May 21, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K

Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments.

Sharon Pei Yi Chan1, Masturah Bte Mohd Abdul Rashid2, Jhin Jieh Lim2

  • 1Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, #12-01 Centre for Translational Medicine, Singapore, 117599, Republic of Singapore.

NPJ Precision Oncology
|March 23, 2025
PubMed
Summary

This study shows the Quadratic Phenotypic Optimization Platform (QPOP) can predict soft tissue sarcoma (STS) treatment responses. QPOP identified a novel drug combination with superior efficacy for STS patients.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Related Experiment Videos

Last Updated: May 21, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Soft tissue sarcomas (STS) are rare, heterogeneous cancers with poor prognoses.
  • Current treatments, mainly cytotoxic chemotherapy, offer limited efficacy due to lack of targeted therapies.

Purpose of the Study:

  • To evaluate the Quadratic Phenotypic Optimization Platform (QPOP) for predicting treatment response in STS.
  • To explore QPOP's utility in designing effective combination therapies for STS.

Main Methods:

  • QPOP was used to screen 45 primary STS patient samples against various agents.
  • Drug sensitivity data was correlated with patient outcomes.
  • A combination of AZD5153 (BET inhibitor) and pazopanib (multi-kinase blocker) was identified and validated.

Main Results:

  • QPOP predictions showed improved or concordant patient outcomes.
  • The identified drug combination demonstrated superior efficacy compared to standard regimens.
  • In vitro and in vivo models confirmed synergistic interaction and repression of MYC pathways.

Conclusions:

  • QPOP shows promise as a predictive tool for STS treatment response.
  • This platform can guide the development of novel, effective combination therapies for STS.
  • Preliminary clinical evidence supports QPOP's role in personalized STS treatment strategies.